| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/BJH.14688 |
| P698 | PubMed publication ID | 28466487 |
| P50 | author | Narendranath Epperla | Q87982418 |
| P2093 | author name string | Svetomir N Markovic | |
| Stephen M Ansell | |||
| Thomas E Witzig | |||
| David J Inwards | |||
| Grzegorz S Nowakowski | |||
| Ivana N Micallef | |||
| Luis F Porrata | |||
| Patrick B Johnston | |||
| Thomas M Habermann | |||
| William R Macon | |||
| Gregory A Wiseman | |||
| Joseph P Colgan | |||
| Kay M Ristow | |||
| Anthony Q Pham | |||
| Brian L Burnette | |||
| P2860 | cites work | Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma | Q33380246 |
| Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study | Q33389503 | ||
| An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma | Q33393623 | ||
| Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial | Q33406742 | ||
| Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study | Q33412158 | ||
| Higher grade transformation of follicular lymphoma: phenotypic tumor progression associated with diverse genetic lesions | Q35213325 | ||
| Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. | Q36054254 | ||
| Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms | Q36869113 | ||
| Rearrangement of human cell homologous chromosome domains in response to ionizing radiation | Q36882722 | ||
| Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource | Q37132380 | ||
| Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report | Q37877728 | ||
| Molecular nature of radiation injury and DNA repair disorders associated with radiosensitivity. | Q37986682 | ||
| Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma | Q40038511 | ||
| Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. | Q40533698 | ||
| Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma | Q40733712 | ||
| Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma | Q41211534 | ||
| Long-term follow up of rates of secondary malignancy and late relapse of two trials using radioimmunotherapy consolidation following induction chemotherapy for previously untreated indolent lymphoma. | Q41444373 | ||
| Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma). | Q43457873 | ||
| 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial. | Q44762135 | ||
| Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). | Q46700738 | ||
| Ionizing radiation-induced instant pairing of heterochromatin of homologous chromosomes in human cells. | Q47431886 | ||
| Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances. | Q51871229 | ||
| Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. | Q53444277 | ||
| 131I-tositumomab therapy as initial treatment for follicular lymphoma. | Q54682444 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| P304 | page(s) | 427-433 | |
| P577 | publication date | 2017-05-03 | |
| P1433 | published in | British Journal of Haematology | Q4970200 |
| P1476 | title | Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma | |
| P478 | volume | 178 |
| Q90589538 | Exposure to ibritumomab tiuxetan and incidence of treatment-related myeloid neoplasms among older patients with B-cell lymphoma: a population-based study |
| Q55026647 | Indolent lymphoma with composite histology and simultaneous transformation at initial diagnosis exhibit clinical features similar to de novo diffuse large B-cell lymphoma. |
| Q52336772 | Novel acquisitions on biology and management of transformed follicular lymphoma. |
| Q57074546 | Therapy-related myeloid neoplasms: clinical perspectives |
Search more.